Suppr超能文献

在大鼠模型中,重组人尿激酶对已建立的博来霉素诱导的肺纤维化有部分逆转作用。

Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model.

作者信息

Hart D A, Whidden P, Green F, Henkin J, Woods D E

机构信息

Department of Microbiology and Infectious Diseases, University of Calgary Health Sciences Centre, Alberta.

出版信息

Clin Invest Med. 1994 Apr;17(2):69-76.

PMID:7516275
Abstract

Pulmonary fibrosis was induced in male Sprague-Dawley rats by intratracheal instillation of bleomycin. By 30 d post-bleomycin, the lungs exhibited elevated interstitial collagen levels. Thirty d after exposure to bleomycin, animals were further treated by intratracheal administration of phosphate-buffered saline (PBS) or 12,500 units of recombinant human urokinase (rh-UK). Three days later, the animals were sacrificed and the lungs fixed, sectioned, and assessed for fibrosis. The presence of interstitial collagen was quantitated using a BioQuant Image Analysis System (R and M Biometrics, Inc., Nashville, TN). Urokinase treatment of animals with established pulmonary fibrosis induced by exposure to 0.5 units of bleomycin was found to diminish the collagen content of lungs to near control levels by 3 d post-UK treatment. By 36 d post-UK treatment (66 d post-bleomycin), values for interstitial collagen were again partially elevated, indicating that UK treatment interfered with established fibrosis but did not stop the bleomycin-mediated process. However, the extent of fibrosis was less than that observed in lungs from non-UK treated animals 66 d post-bleomycin. UK treatment initiated 63 d post-bleomycin exposure again revealed a decline in the extent of fibrosis, but the values did not return to baseline levels. A repeat of the short-term experiment with a higher dose of bleomycin (0.85 units) again revealed that UK treatment was effective in diminishing the extent of fibrosis from 22% to 12% collagen. These results indicate that exogenous UK may be an effective therapeutic modality in the treatment of pulmonary fibrosis induced by some stimuli or developing in association with diseases such as scleroderma.

摘要

通过气管内滴注博来霉素在雄性Sprague-Dawley大鼠中诱导肺纤维化。博来霉素给药后30天,肺间质胶原水平升高。暴露于博来霉素30天后,动物通过气管内给予磷酸盐缓冲盐水(PBS)或12,500单位重组人尿激酶(rh-UK)进行进一步治疗。三天后,处死动物,将肺固定、切片并评估纤维化情况。使用BioQuant图像分析系统(R和M Biometrics公司,田纳西州纳什维尔)对间质胶原的存在进行定量。发现用尿激酶治疗由0.5单位博来霉素诱导的已建立肺纤维化的动物,在尿激酶治疗后3天,肺胶原含量降至接近对照水平。尿激酶治疗后36天(博来霉素给药后66天),间质胶原值再次部分升高,表明尿激酶治疗干扰了已建立的纤维化,但未阻止博来霉素介导的过程。然而,纤维化程度低于博来霉素给药后66天未用尿激酶治疗的动物肺中的纤维化程度。在博来霉素暴露后63天开始的尿激酶治疗再次显示纤维化程度下降,但值未恢复到基线水平。用更高剂量的博来霉素(0.85单位)重复短期实验再次表明,尿激酶治疗有效地将纤维化程度从22%降至12%的胶原含量。这些结果表明,外源性尿激酶可能是治疗由某些刺激诱导或与硬皮病等疾病相关发展的肺纤维化的有效治疗方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验